IO Biotech (IOBT) Competitors

Atyr PHARMA (NASDAQ:ATYR) and IO Biotech (NASDAQ:IOBT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, community ranking, media sentiment, institutional ownership and valuation.

Do institutionals and insiders hold more shares of ATYR or IOBT?

61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 54.8% of IO Biotech shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by insiders. Comparatively, 4.8% of IO Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has preferable valuation and earnings, ATYR or IOBT?

Atyr PHARMA has higher revenue and earnings than IO Biotech. Atyr PHARMA is trading at a lower price-to-earnings ratio than IO Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$235K	2,083.07	-$50.39M	-$0.81	-6.79
IO Biotech	N/A	N/A	-$86.08M	-$1.37	-1.08

Does the MarketBeat Community believe in ATYR or IOBT?

IO Biotech received 11 more outperform votes than Atyr PHARMA when rated by MarketBeat users. However, 100.00% of users gave Atyr PHARMA an outperform vote while only 92.86% of users gave IO Biotech an outperform vote.

Company	Underperform	Outperform
Atyr PHARMA	Outperform Votes 15 100.00%	Underperform Votes No Votes
IO Biotech	Outperform Votes 26 92.86%	Underperform Votes 2 7.14%

Does the media favor ATYR or IOBT?

In the previous week, Atyr PHARMA had 6 more articles in the media than IO Biotech. MarketBeat recorded 9 mentions for Atyr PHARMA and 3 mentions for IO Biotech. IO Biotech's average media sentiment score of 1.20 beat Atyr PHARMA's score of 0.60 indicating that IO Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atyr PHARMA	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IO Biotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ATYR or IOBT?

Atyr PHARMA has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, IO Biotech has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500.

Is ATYR or IOBT more profitable?

Atyr PHARMA's return on equity of -79.44% beat IO Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
IO Biotech	N/A	-86.56%	-75.24%

Do analysts rate ATYR or IOBT?

Atyr PHARMA presently has a consensus price target of $18.60, suggesting a potential upside of 238.18%. IO Biotech has a consensus price target of $9.33, suggesting a potential upside of 530.63%. Given IO Biotech's stronger consensus rating and higher possible upside, analysts plainly believe IO Biotech is more favorable than Atyr PHARMA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14
IO Biotech	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Summary

Atyr PHARMA beats IO Biotech on 10 of the 16 factors compared between the two stocks.